11. Myasthenia gravis Disease details / Clinical trials / Drug dev / DR info

Clinical trials : 332 /  Drugs : 234 - (DrugBank : 81) / Drug target genes : 45 - Drug target pathways : 127

Drugs and their primary sponsors and trial info
(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide   
   Alexion Pharmaceuticals
      2022   Phase 2   EUCTR2021-001229-26-ES   Canada;Germany;Italy;Korea, Democratic People's Republic of;Spain;Taiwan;United States;
ALN-CC5   
   REGENERON PHARMACEUTICALS, INC.
      2021   Phase 3   EUCTR2020-003272-41-IT   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
   Regeneron Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2020-003272-41-ES   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2022   Phase 3   EUCTR2020-003272-41-DE   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003272-41-PL   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
ALXN1210   
   ALEXION PHARMACEUTICALS INCORPORATED
      2019   Phase 3   EUCTR2018-003243-39-IT   Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States;
   Alexion Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2018-003243-39-PT   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-003243-39-GB   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-003243-39-CZ   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003243-39-NL   Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003243-39-ES   Austria;Canada;Denmark;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Spain;Switzerland;United States;
      2019   Phase 3   EUCTR2018-003243-39-DK   Austria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003243-39-DE   Austria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003243-39-AT   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States;
ALXN1830   
   Alexion Pharmaceuticals
      2022   Phase 2   NCT04982289   United States;
ALXN2050   
   Alexion Pharmaceuticals
      2022   Phase 2   EUCTR2021-001229-26-ES   Canada;Germany;Italy;Korea, Democratic People's Republic of;Spain;Taiwan;United States;
      2021   Phase 2   NCT05218096   United States;
AMIFAMPRIDINA   
   FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
      2015   Phase 2   EUCTR2015-003127-62-IT   Italy;
ARGX-113   
   ARGEN-X BVBA
      2018   Phase 3   EUCTR2018-002133-37-IT   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-002132-25-IT   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-002938-73-IT   Belgium;Canada;Italy;Netherlands;Poland;Spain;Sweden;United States;
   ARGENX BV
      2022   Phase 3   EUCTR2021-002504-12-IT   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
   Argenx BVBA
      2018   Phase 3   EUCTR2018-002132-25-DK   Belgium;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-002938-73-NL   Belgium;Canada;Italy;Netherlands;Poland;Spain;Sweden;United States;
      2016   Phase 2   EUCTR2016-002938-73-ES   Belgium;Canada;Italy;Netherlands;Poland;Spain;Sweden;United States;
      2016   Phase 2   EUCTR2016-002938-73-BE   Belgium;Canada;Italy;Netherlands;Poland;Spain;Sweden;United States;
   argenx
      2019   Phase 3   NCT03770403   Belgium;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;United States;
      2018   Phase 3   NCT03669588   Belgium;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;United Kingdom;United States;
      2016   Phase 2   NCT02965573   Belgium;Canada;Italy;Netherlands;Poland;Spain;Sweden;United States;
   argenx BV
      2021   Phase 3   EUCTR2021-002504-12-ES   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-005841-18-Outside-EU/EEA   Canada;Georgia;United Kingdom;United States;
   argenx BVBA
      2019   Phase 3   EUCTR2018-002133-37-NL   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002133-37-HU   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002133-37-DK   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002133-37-DE   Belgium;Canada;Czech Republic;Czechia;Denmark;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;United States;
      2019   Phase 3   EUCTR2018-002133-37-CZ   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002133-37-BE   Belgium;Canada;Czech Republic;Czechia;Denmark;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;United States;
      2019   Phase 3   EUCTR2018-002132-25-NL   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002132-25-HU   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002132-25-FR   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002132-25-DE   Belgium;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002132-25-CZ   Belgium;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002132-25-BE   Belgium;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States;
ATG (rabbit)   
   Northwestern University
      2002   Phase 1   NCT00424489   United States;
AZA   
   Qualitix Clinical Research Co., Ltd.
      2009   -   NCT00997412   -
Abatacept Injection   
   Johns Hopkins University
      2017   Early Phase 1   NCT03059888   United States;
Acetaminophen   
   MILLENNIUM PHARMACEUTICALS, INC.
      2020   Phase 2   EUCTR2019-003383-47-IT   Canada;Italy;Poland;Serbia;Spain;United States;
Acetominofene   
   MILLENNIUM PHARMACEUTICALS, INC.
      2020   Phase 2   EUCTR2019-003383-47-IT   Canada;Italy;Poland;Serbia;Spain;United States;
Acetylcholine   
   XiaoYong Liu
      2021   -   NCT05091177   China;
Amifampridina fosfato   
   CATALYST PHARMACEUTICALS INC.
      2018   Phase 3   EUCTR2017-004777-14-IT   Canada;Italy;United States;
      2018   Phase 3   EUCTR2017-004018-25-IT   Canada;Italy;United States;
Amifampridine Phosphate   
   Catalyst Pharmaceuticals, Inc.
      2018   Phase 3   NCT03579966   United States;
      2018   Phase 3   NCT03304054   United States;
Anti-C5 antibody   
   Alexion Pharmaceuticals Inc.
      2009   -   EUCTR2009-014669-13-GB   United Kingdom;
Anti-Thymocyte Globulin   
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
Apraclonidine Hcl Oph Soln   
   American University of Beirut Medical Center
      2020   Phase 2   NCT05045248   Lebanon;
Argx-113   
   ARGENX BV
      2021   Phase 2;Phase 3   EUCTR2020-005841-18-IT   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
   argenx BV
      2022   Phase 2;Phase 3   EUCTR2020-005841-18-DE   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-005841-18-ES   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2020-005841-18-BE   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2021-002460-46-FR   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-005841-18-PL   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-005841-18-NL   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-005841-18-FR   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Autologous Hematopoietic Stem Cell Transplantation   
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
Azathioprine   
   Duke University
      2018   -   NCT03490539   Canada;United States;
   First Affiliated Hospital, Sun Yat-Sen University
      2012   Phase 3   NCT01727193   China;
   Neurology Department of the 940th Hospital of Joint Logistics Support force of Chinese People's Liberation Army
      2018   -   ChiCTR1900024692   China;
B-peptide-CRM197 conjugate   
   CuraVac Europe SA
      2017   Phase 2;Phase 3   EUCTR2017-000323-27-NL   Belgium;Netherlands;
      2017   Phase 2;Phase 3   EUCTR2017-000323-27-BE   Belgium;Netherlands;
BBR 2778   
   ISTITUTO NEUROLOGICO CARLO BESTA
      2008   -   EUCTR2007-002817-37-IT   Italy;
BENLYSTA® (belimumab)   
   GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
      2011   -   EUCTR2011-002068-26-IT   Canada;Germany;Italy;United States;
   GlaxoSmithKline Research & Development Limited
      2011   -   EUCTR2011-002068-26-DE   Canada;Germany;Italy;United States;
Balance   
   individualized
      2021   -   JPRN-UMIN000044102   Africa;
Belimumab   
   GlaxoSmithKline
      2013   Phase 2   NCT01480596   Canada;Germany;Italy;United States;
Benlysta (belimumab)   
   GlaxoSmithKline Research & Development Limited
      2011   -   EUCTR2011-002068-26-DE   Canada;Germany;Italy;United States;
Bexsero   
   REGENERON PHARMACEUTICALS, INC.
      2021   Phase 3   EUCTR2020-003272-41-IT   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
Bortezomib   
   Charite University, Berlin, Germany
      2014   Phase 2   NCT02102594   Germany;
CD19-directed humanised afucosylated monoclonal antibody   
   Viela Bio, Inc.
      2021   Phase 3   EUCTR2020-000949-14-DK   Argentina;Belarus;Brazil;Canada;China;Denmark;France;Germany;India;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United States;
      2021   Phase 3   EUCTR2020-000949-14-DE   Argentina;Belarus;Brazil;Canada;China;Denmark;France;Germany;India;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000949-14-FR   Argentina;Australia;Belarus;Brazil;Canada;China;Denmark;Finland;France;Germany;Guatemala;India;Israel;Italy;Japan;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
CELLCEPT   
   ASPREVA PHARMACEUTICALS CORPORATION
      2005   -   EUCTR2004-000596-34-IT   Czech Republic;Hungary;Italy;Spain;
CFZ533   
   Novartis Pharma Services AG
      2015   Phase 2   EUCTR2015-000097-35-DK   Canada;Denmark;Germany;Russian Federation;Taiwan;
      2015   Phase 2   EUCTR2015-000097-35-DE   Canada;Denmark;Germany;Russian Federation;Taiwan;
   Novartis Pharmaceuticals
      2015   Phase 2   NCT02565576   Canada;Denmark;Germany;Russian Federation;Taiwan;
CK-2017357   
   Cytokinetics
      2010   Phase 2   NCT01268280   United States;
CV-MG01   
   CuraVac
      2018   Phase 2/Phase 3   NCT03165435   Belgium;Netherlands;
      2016   Phase 1/Phase 2   NCT02609022   Belgium;
   CuraVac Europe SA
      2017   Phase 2;Phase 3   EUCTR2017-000323-27-NL   Belgium;Netherlands;
      2017   Phase 2;Phase 3   EUCTR2017-000323-27-BE   Belgium;Netherlands;
Carmustine   
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
CellCept   
   F.Hoffmann-La Roche Ltd.
      2005   -   EUCTR2004-000596-34-CZ   Czech Republic;Hungary;Italy;Spain;
CellCept 500 mg film-coated tablets   
   F. Hoffmann-La Roche Ltd
      2005   Phase 3   EUCTR2004-000596-34-ES   Czech Republic;Hungary;Italy;Spain;
   F. Hoffmann-La Roche Ltd as part of the Aspreva Rare Disease Program
      2005   -   EUCTR2004-000596-34-HU   Czech Republic;Hungary;Italy;Spain;
CellCept 500 mg tablets   
   Aspreva Pharmaceutical Corporation
      2005   -   EUCTR2005-000343-28-GB   Germany;Italy;Spain;United Kingdom;
CellCept®500 mg tablets   
   F. Hoffmann-La Roche Ltd
      2005   Phase 3   EUCTR2004-000596-34-ES   Czech Republic;Hungary;Italy;Spain;
   F. Hoffmann-La Roche Ltd as part of the Aspreva Rare Disease Program
      2005   -   EUCTR2004-000596-34-HU   Czech Republic;Hungary;Italy;Spain;
Cellcept   
   ASPREVA PHARMACEUTICALS CORPORATION
      2006   -   EUCTR2005-000343-28-IT   Germany;Italy;Spain;United Kingdom;
Cemdisiran   
   REGENERON PHARMACEUTICALS, INC.
      2021   Phase 3   EUCTR2020-003272-41-IT   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
   Regeneron Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2020-003272-41-ES   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2022   Phase 3   EUCTR2020-003272-41-DE   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003272-41-PL   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
Cladrybine   
   Medical University of Lublin
      2021   Phase 2   EUCTR2020-005762-34-PL   Poland;
Cyclophosphamide   
   Northwestern University
      2002   Phase 1   NCT00424489   United States;
Cyclosporine   
   Neurology Department of the 940th Hospital of Joint Logistics Support force of Chinese People's Liberation Army
      2018   -   ChiCTR1900024692   China;
Cytarabine   
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
DAS-001   
   DAS-MG, Inc
      2021   Phase 2   NCT04226170   United States;
DIFENIDRAMINA CLORIDRATO   
   MILLENNIUM PHARMACEUTICALS, INC.
      2020   Phase 2   EUCTR2019-003383-47-IT   Canada;Italy;Poland;Serbia;Spain;United States;
Descartes-08   
   Cartesian Therapeutics
      2019   Phase 1/Phase 2   NCT04146051   United States;
Diphenhydramine hydrochloride   
   MILLENNIUM PHARMACEUTICALS, INC.
      2020   Phase 2   EUCTR2019-003383-47-IT   Canada;Italy;Poland;Serbia;Spain;United States;
EN101   
   Ester Neuroscience Ltd
      2006   Phase 2   EUCTR2005-002740-26-GB   United Kingdom;
EPHEDRINE HYDROCHLORIDE   
   Leiden University Medical Center
      2014   -   EUCTR2014-001355-23-NL   Netherlands;
Eculizumab   
   Alexion Pharmaceuticals
      2018   Phase 3   NCT03759366   Japan;Netherlands;United States;
      2014   Phase 3   NCT02301624   Argentina;Belgium;Brazil;Canada;Czechia;Denmark;Finland;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Sweden;Turkey;United Kingdom;United States;
      2013   Phase 3   NCT01997229   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Spain;Sweden;Turkey;United Kingdom;United States;
      2008   Phase 2   NCT00727194   Canada;United Kingdom;United States;
   Alexion Pharmaceuticals Inc.
      2009   -   EUCTR2009-014669-13-GB   United Kingdom;
Efgartigimod   
   ARGEN-X BVBA
      2018   Phase 3   EUCTR2018-002133-37-IT   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-002132-25-IT   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States;
   ARGENX BV
      2022   Phase 3   EUCTR2021-002504-12-IT   Austria;Belgium;Canada;France;Georgia;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
   Argenx BVBA
      2018   Phase 3   EUCTR2018-002132-25-DK   Belgium;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States;
   argenx
      2021   -   NCT04777734   -
   argenx BVBA
      2019   Phase 3   EUCTR2018-002133-37-NL   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002132-25-NL   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Sweden;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002132-25-HU   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002132-25-FR   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002132-25-DE   Belgium;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002132-25-CZ   Belgium;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002132-25-BE   Belgium;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Sweden;United Kingdom;United States;
Efgartigimod IV   
   ARGENX BV
      2021   Phase 3   EUCTR2020-004085-19-IT   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
   argenx
      2021   Phase 3   NCT04735432   Belgium;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States;
      2021   Phase 2/Phase 3   NCT04833894   Belgium;France;Georgia;Poland;Spain;
   argenx BV
      2021   Phase 3   EUCTR2020-004085-19-NL   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004085-19-HU   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004085-19-DE   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004085-19-BE   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
Efgartigimod PH20 SC   
   ARGENX BV
      2021   Phase 3   EUCTR2020-004086-38-IT   Belgium;Bosnia and Herzegovina;Canada;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004085-19-IT   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
   argenx
      2021   Phase 3   NCT04818671   Belgium;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States;
      2021   Phase 3   NCT04735432   Belgium;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States;
   argenx BV
      2021   Phase 3   EUCTR2020-004086-38-NL   Belgium;Bosnia and Herzegovina;Canada;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004086-38-HU   Belgium;Bosnia and Herzegovina;Canada;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004086-38-ES   Belgium;Bosnia and Herzegovina;Canada;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004086-38-DE   Belgium;Bosnia and Herzegovina;Canada;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004086-38-BE   Belgium;Bosnia and Herzegovina;Canada;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004085-19-NL   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004085-19-HU   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004085-19-DE   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004085-19-BE   Belgium;Bosnia and Herzegovina;Czechia;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
Efgartigimod concentrate for solution for infusion 20 mg/mL   
   argenx
      2021   Phase 3   NCT04980495   Georgia;Poland;Spain;United States;
Etoposide   
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
FIRDAPSE - 10 MG - COMPRESSE - USO ORALE - BLISTER(ALU/PVC/PVDC) 100 X 1 COMPRESSE   
   CATALYST PHARMACEUTICALS INC.
      2018   Phase 3   EUCTR2017-004777-14-IT   Canada;Italy;United States;
      2018   Phase 3   EUCTR2017-004018-25-IT   Canada;Italy;United States;
   FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
      2015   Phase 2   EUCTR2015-003127-62-IT   Italy;
Fc- and CDR-modified humanised monoclonal antibody against C5   
   Alexion Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2018-003243-39-PT   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-003243-39-GB   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-003243-39-CZ   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003243-39-NL   Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003243-39-ES   Austria;Canada;Denmark;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Spain;Switzerland;United States;
      2019   Phase 3   EUCTR2018-003243-39-DK   Austria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003243-39-DE   Austria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003243-39-AT   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States;
G-CSF   
   Northwestern University
      2002   Phase 1   NCT00424489   United States;
GAMUNEX   
   Grifols Therapeutics Inc.
      2016   Phase 2   EUCTR2014-003997-18-DE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 3   EUCTR2013-005098-28-RO   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Latvia;Poland;Romania;Russian Federation;
      2015   Phase 3   EUCTR2013-005098-28-PL   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Latvia;Poland;Romania;Russian Federation;South Africa;
      2015   Phase 3   EUCTR2013-005098-28-BE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Israel;Korea, Republic of;Latvia;Netherlands;Poland;Romania;Russian Federation;South Africa;
      2015   Phase 2   EUCTR2014-003997-18-LT   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2014-003997-18-HU   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2014-003997-18-EE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2014-003997-18-CZ   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2014-003997-18-BE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2013-005099-17-LT   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2013-005099-17-HU   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2013-005099-17-DE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2013-005099-17-CZ   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2013-005099-17-BE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2014   Phase 3   EUCTR2013-005098-28-HU   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Latvia;Netherlands;Poland;Romania;Russian Federation;South Africa;
   Grifols Therapeutics LLC
      2015   Phase 3   EUCTR2013-005098-28-LV   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Latvia;Poland;Romania;Russian Federation;South Africa;
      2015   Phase 3   EUCTR2013-005098-28-EE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Latvia;Poland;Romania;Russian Federation;South Africa;
      2015   Phase 2   EUCTR2013-005099-17-EE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
   Grifols Therapeutics LLC.
      2015   Phase 3   EUCTR2013-005098-28-CZ   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Latvia;Poland;Romania;Russian Federation;South Africa;
GB-0998 (Intravenous immunoglobulin)   
   Benesis Corporation
      2007   Phase 3   NCT00515450   Japan;
GSK1550188   
   GlaxoSmithKline Research & Development Limited
      2011   -   EUCTR2011-002068-26-DE   Canada;Germany;Italy;United States;
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)   
   Muscular Dystrophy Association
      2012   Phase 0   NCT01555580   United States;
HBM9161 Injection (340 mg)   
   Harbour BioMed (Guangzhou) Co. Ltd.
      2020   Phase 2   NCT04346888   China;
HBM9161 Injection (680mg and 340 mg)   
   Harbour BioMed (Guangzhou) Co. Ltd.
      2020   Phase 2   NCT04346888   China;
HBM9161 Injection (680mg)   
   Harbour BioMed (Guangzhou) Co. Ltd.
      2021   Phase 3   NCT05039190   China;
HIZENTRA ®   
   Mazen Dimachkie, MD
      2015   Phase 2   NCT02100969   Canada;United States;
HUMAN NORMAL IMMUNOGLOBULIN (IV)   
   Grifols Therapeutics Inc.
      2016   Phase 2   EUCTR2014-003997-18-DE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 3   EUCTR2013-005098-28-RO   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Latvia;Poland;Romania;Russian Federation;
      2015   Phase 3   EUCTR2013-005098-28-PL   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Latvia;Poland;Romania;Russian Federation;South Africa;
      2015   Phase 3   EUCTR2013-005098-28-BE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Israel;Korea, Republic of;Latvia;Netherlands;Poland;Romania;Russian Federation;South Africa;
      2015   Phase 2   EUCTR2014-003997-18-LT   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2014-003997-18-HU   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2014-003997-18-EE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2014-003997-18-CZ   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2014-003997-18-BE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2013-005099-17-LT   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2013-005099-17-HU   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2013-005099-17-DE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2013-005099-17-CZ   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2013-005099-17-BE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2014   Phase 3   EUCTR2013-005098-28-HU   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Latvia;Netherlands;Poland;Romania;Russian Federation;South Africa;
   Grifols Therapeutics LLC
      2015   Phase 3   EUCTR2013-005098-28-LV   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Latvia;Poland;Romania;Russian Federation;South Africa;
      2015   Phase 3   EUCTR2013-005098-28-EE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Latvia;Poland;Romania;Russian Federation;South Africa;
      2015   Phase 2   EUCTR2013-005099-17-EE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
   Grifols Therapeutics LLC.
      2015   Phase 3   EUCTR2013-005098-28-CZ   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Latvia;Poland;Romania;Russian Federation;South Africa;
Hematopoietic Stem Cell Transplantation   
   Northwestern University
      2002   Phase 1   NCT00424489   United States;
Hidrocloruro de efedrina   
   Leiden University Medical Center
      2014   -   EUCTR2014-001355-23-NL   Netherlands;
Human normal immunoglobulin G (IgG)   
   University of Alberta
      2014   Phase 3   NCT02774239   Canada;
IGIV-C   
   Grifols Therapeutics LLC
      2015   Phase 3   NCT02413580   Argentina;Belgium;Canada;Czech Republic;Czechia;Estonia;France;Hungary;Latvia;Poland;Romania;Russian Federation;South Africa;
      2015   Phase 2   NCT02473965   Belgium;Canada;Czech Republic;Czechia;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   NCT02473952   Belgium;Canada;Czech Republic;Czechia;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
IMMUNOGLOBULIN G   
   Vall d'Hebron Institut de Recerca (VHIR)
      2012   -   EUCTR2012-001544-21-ES   Spain;
IVIG   
   University Health Network, Toronto
      2007   Phase 4   NCT01179893   Canada;
Immune Globulin (Human), Caprylate/Chromatography Purified   
   Grifols Therapeutics Inc.
      2015   Phase 3   EUCTR2013-005098-28-RO   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Latvia;Poland;Romania;Russian Federation;
      2015   Phase 3   EUCTR2013-005098-28-PL   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Latvia;Poland;Romania;Russian Federation;South Africa;
      2015   Phase 3   EUCTR2013-005098-28-BE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Israel;Korea, Republic of;Latvia;Netherlands;Poland;Romania;Russian Federation;South Africa;
      2014   Phase 3   EUCTR2013-005098-28-HU   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Latvia;Netherlands;Poland;Romania;Russian Federation;South Africa;
   Grifols Therapeutics LLC
      2015   Phase 3   EUCTR2013-005098-28-LV   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Latvia;Poland;Romania;Russian Federation;South Africa;
      2015   Phase 3   EUCTR2013-005098-28-EE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Latvia;Poland;Romania;Russian Federation;South Africa;
   Grifols Therapeutics LLC.
      2015   Phase 3   EUCTR2013-005098-28-CZ   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Latvia;Poland;Romania;Russian Federation;South Africa;
Immune Globulin (Human), Caprylate/Chromatography Purified (IGIV-C)   
   Grifols Therapeutics Inc.
      2016   Phase 2   EUCTR2014-003997-18-DE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2014-003997-18-LT   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2014-003997-18-HU   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2014-003997-18-EE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2014-003997-18-CZ   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2014-003997-18-BE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2013-005099-17-LT   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2013-005099-17-HU   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2013-005099-17-DE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2013-005099-17-CZ   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
      2015   Phase 2   EUCTR2013-005099-17-BE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
   Grifols Therapeutics LLC
      2015   Phase 2   EUCTR2013-005099-17-EE   Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Lithuania;Poland;United States;
Immune globulin   
   University of Texas
      1995   -   NCT00004682   -
Inebilizumab   
   Katayama Sota
      2021   Phase 3   JPRN-jRCT2021210003   Argentina;Belarus;Brazil;Canada;China;Denmark;France;Germany;India;Israel;Italy;Japan;Poland;Russia;South Korea;Spain;Taiwan;Turkey;USA;Ukraine;
   Viela Bio
      2020   Phase 3   NCT04524273   Argentina;Belarus;Brazil;Canada;China;Denmark;France;Germany;India;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United States;
Influenza vaccine   
   LUMC
      2016   Phase 4   EUCTR2016-003138-26-NL   Netherlands;
Intravenous ImmuneGlobulin   
   University Health Network, Toronto
      2004   Phase 3   NCT00306033   Canada;
Intravenous immunoglobulin + subcutaneous immunoglobulin (SCIG)   
   University Health Network, Toronto
      2020   Phase 2   NCT04728425   Canada;
JNJ-80202135   
   JANSSEN CILAG INTERNATIONAL NV
      2021   Phase 3   EUCTR2020-005732-29-IT   Australia;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
   Janssen-Cilag International N.V.
      2022   Phase 3   EUCTR2020-005732-29-DK   Australia;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-005732-29-SE   Australia;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-005732-29-ES   Australia;Belgium;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-005732-29-DE   Australia;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-005732-29-CZ   Australia;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
Leflunomide   
   First Affiliated Hospital, Sun Yat-Sen University
      2012   Phase 3   NCT01727193   China;
M281   
   JANSSEN CILAG INTERNATIONAL NV
      2021   Phase 3   EUCTR2020-005732-29-IT   Australia;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
   Janssen-Cilag International N.V.
      2022   Phase 3   EUCTR2020-005732-29-DK   Australia;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-005732-29-SE   Australia;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-005732-29-ES   Australia;Belgium;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-005732-29-DE   Australia;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-005732-29-CZ   Australia;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
   MOMENTA PHARMACEUTICALS, Inc
      2019   Phase 2   EUCTR2018-003618-41-IT   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States;
   Momenta Pharmaceuticals, Inc.
      2019   Phase 2   NCT03896295   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 2   NCT03772587   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003618-41-PL   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003618-41-GB   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003618-41-DE   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003618-41-BE   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002247-28-GB   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States;
M281 Injection   
   MOMENTA PHARMACEUTICALS, Inc
      2019   Phase 2   EUCTR2018-002247-28-IT   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States;
   Momenta Pharmaceuticals, Inc.
      2019   Phase 2   EUCTR2018-003618-41-ES   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002247-28-PL   Belgium;Canada;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002247-28-BE   Belgium;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States;
      2018   Phase 2   EUCTR2018-002247-28-ES   Belgium;Canada;France;Germany;Italy;Poland;Spain;United Kingdom;United States;
MENINGOCOCCAL GROUP A OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (beta197) M8 (CRM197) PROTEIN   
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2   EUCTR2021-001229-26-IT   Canada;Germany;Italy;Korea, Republic of;Spain;Taiwan;United States;
MENINGOCOCCAL GROUP A OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (ß197) M8 (CRM197) PROTEIN   
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2   EUCTR2021-001229-26-IT   Canada;Germany;Italy;Korea, Republic of;Spain;Taiwan;United States;
MENINGOCOCCAL GROUP W OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (beta197) M8 (CRM197) PROTEIN   
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2   EUCTR2021-001229-26-IT   Canada;Germany;Italy;Korea, Republic of;Spain;Taiwan;United States;
MENINGOCOCCAL GROUP W OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (ß197) M8 (CRM197) PROTEIN   
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2   EUCTR2021-001229-26-IT   Canada;Germany;Italy;Korea, Republic of;Spain;Taiwan;United States;
MENINGOCOCCAL GROUP Y OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (Â197) M8 (CRM197) PROTEIN   
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2   EUCTR2021-001229-26-IT   Canada;Germany;Italy;Korea, Republic of;Spain;Taiwan;United States;
METILPREDNISOLONE   
   MILLENNIUM PHARMACEUTICALS, INC.
      2020   Phase 2   EUCTR2019-003383-47-IT   Canada;Italy;Poland;Serbia;Spain;United States;
MONARSEN   
   Ester Neuroscience Ltd
      2006   Phase 2   EUCTR2005-002740-26-GB   United Kingdom;
Magnesium sulfate   
   The University of Hong Kong-Shenzhen Hospital
      2016   -   ChiCTR1800017696   China;
Melphalan   
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
Menveo   
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2   EUCTR2021-001229-26-IT   Canada;Germany;Italy;Korea, Republic of;Spain;Taiwan;United States;
Mesna   
   Northwestern University
      2002   Phase 1   NCT00424489   United States;
Mestinon   
   Aarhus University
      2017   Phase 4   EUCTR2017-002599-15-DK   Denmark;
Methotrexate   
   University of Kansas Medical Center
      2009   Phase 2   NCT00814138   Canada;United States;
   Xuan Wu Hospital, Capital Medical University
      2014   Phase 4   ChiCTR-IPR-15006081   -
Methylprednisolone   
   Koh Jinsoo
      2021   -   JPRN-jRCTs051200137   Japan;
   MILLENNIUM PHARMACEUTICALS, INC.
      2020   Phase 2   EUCTR2019-003383-47-IT   Canada;Italy;Poland;Serbia;Spain;United States;
   Northwestern University
      2002   Phase 1   NCT00424489   United States;
Metilprdnisolone   
   MILLENNIUM PHARMACEUTICALS, INC.
      2020   Phase 2   EUCTR2019-003383-47-IT   Canada;Italy;Poland;Serbia;Spain;United States;
Mutagrip   
   Philipps-University
      2006   -   EUCTR2006-004374-27-DE   Germany;
Mycophenolate mofetil   
   Aspreva Pharmaceutical Corporation
      2005   -   EUCTR2005-000343-28-GB   Germany;Italy;Spain;United Kingdom;
   Aspreva Pharmaceuticals Corporation
      2005   -   EUCTR2005-000343-28-DE   Germany;Italy;Spain;United Kingdom;
   F. Hoffmann-La Roche Ltd
      2005   Phase 3   EUCTR2004-000596-34-ES   Czech Republic;Hungary;Italy;Spain;
   F. Hoffmann-La Roche Ltd as part of the Aspreva Rare Disease Program
      2005   -   EUCTR2004-000596-34-HU   Czech Republic;Hungary;Italy;Spain;
   FDA Office of Orphan Products Development
      2002   Phase 3   NCT00285350   -
Mycophenolate mofetil (CellCept)   
   Hoffmann-La Roche
      2004   Phase 3   NCT00683969   Canada;Former Serbia and Montenegro;France;Germany;India;Israel;Italy;Mexico;Netherlands;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Mycophenolate mofetil [CellCept]   
   Hoffmann-La Roche
      2004   Phase 3   NCT00408213   Canada;Czech Republic;Former Serbia and Montenegro;France;Germany;Israel;Italy;Mexico;Netherlands;Spain;Ukraine;United Kingdom;United States;
Mycophenolic acid   
   ASPREVA PHARMACEUTICALS CORPORATION
      2006   -   EUCTR2005-000343-28-IT   Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-000596-34-IT   Czech Republic;Hungary;Italy;Spain;
   Qualitix Clinical Research Co., Ltd.
      2009   -   NCT00997412   -
N. MENINGITIDIS GROUP C (STRAIN C11) OLIGOSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197 ADSORBED ON ALUMINUM HYDROXIDE   
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2   EUCTR2021-001229-26-IT   Canada;Germany;Italy;Korea, Republic of;Spain;Taiwan;United States;
Neostigmine   
   XiaoYong Liu
      2021   -   NCT05091177   China;
Nipocalimab   
   JANSSEN CILAG INTERNATIONAL NV
      2021   Phase 3   EUCTR2020-005732-29-IT   Australia;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
   Janssen Research & Development, LLC
      2022   Phase 2/Phase 3   NCT05265273   Canada;Japan;Netherlands;United States;
      2021   Phase 3   NCT04951622   Australia;Belgium;Canada;China;Colombia;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
   Janssen-Cilag International N.V.
      2022   Phase 3   EUCTR2020-005732-29-DK   Australia;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-005732-29-SE   Australia;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-005732-29-ES   Australia;Belgium;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-005732-29-DE   Australia;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-005732-29-CZ   Australia;Belgium;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
   Nakano Masayoshi
      2022   Phase 3   JPRN-jRCT2021210027   Belgium;Canada;China;Colombia;Czechia;Denmark;France;Germany;Italy;Japan;Kingdom Of Great Britain And Northern Ireland;Mexico;Poland;Russian Federation;Spain;Sweden;Turkey;United States Of America;
Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254measured as amount of total protein containing the PorA P1.4   
   REGENERON PHARMACEUTICALS, INC.
      2021   Phase 3   EUCTR2020-003272-41-IT   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
Oxaloacetate   
   University of Kansas Medical Center
      2021   Phase 1   NCT04965987   United States;
PLEX   
   University Health Network, Toronto
      2007   Phase 4   NCT01179893   Canada;
PRIVIGEN   
   Vall d'Hebron Institut de Recerca (VHIR)
      2012   -   EUCTR2012-001544-21-ES   Spain;
PRN2246   
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 3   EUCTR2021-003898-59-IT   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
   Sanofi-Aventis Recherche & Développement
      2022   Phase 3   EUCTR2021-003898-59-PL   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-003898-59-ES   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-003898-59-HU   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
Peripheral Blood Stem Cell Transplantation   
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
Plasmapheresis   
   Benesis Corporation
      2007   Phase 3   NCT00515450   Japan;
Pozelimab   
   REGENERON PHARMACEUTICALS, INC.
      2021   Phase 3   EUCTR2020-003272-41-IT   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
   Regeneron Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2020-003272-41-ES   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2022   Phase 3   EUCTR2020-003272-41-DE   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003272-41-PL   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
Pozelimab (REGN3918) + Cemdisiran   
   Regeneron Pharmaceuticals
      2021   Phase 3   NCT05070858   -
Prednisolone   
   Department of Neurology, Chiba University Graduate School of Medicine
      2012   -   JPRN-UMIN000007679   Japan;
      2012   -   JPRN-UMIN000007671   Japan;
   Koh Jinsoo
      2021   -   JPRN-jRCTs051200137   Japan;
Prednisone   
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
   Michael Benatar
      2011   Phase 3   NCT00995722   Canada;United States;
   The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
      2018   -   ChiCTR1800017564   China;
   Xuan Wu Hospital, Capital Medical University
      2014   Phase 4   ChiCTR-IPR-15006081   -
Prednisone - Azathioprine   
   Assistance Publique - Hôpitaux de Paris
      2009   Phase 4   NCT00987116   France;
Prednisone alone   
   University of Alabama at Birmingham
      2006   Phase 3   NCT00294658   Argentina;Australia;Brazil;Canada;Chile;Germany;Ireland;Italy;Japan;Mexico;Netherlands;Poland;Portugal;South Africa;Spain;Taiwan;Thailand;United Kingdom;United States;
Pyridostigmine   
   Affiliated Jiangmen Traditional Chinese Medicine Hospital of Ji’nan University
      2022   Phase 0   ChiCTR2100047506   China;
   Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine
      2010   Phase 1+Phase 2   ChiCTR-TRC-13004125   China;
   The first affiliated hospital of Guangzhou university of Traditional Chinese medicine
      2012   -   ChiCTR-OCC-13003090   China;
   University of Aarhus
      2018   Phase 4   NCT03510546   Denmark;
Pyridostigmine, Prednisone, Tacrolimus   
   Da, Yuwei, M.D.
      2021   -   NCT04768465   China;
Pyridostigmine, Tacrolimus   
   Da, Yuwei, M.D.
      2021   -   NCT04768465   China;
RC18   
   RemeGen Co., Ltd.
      2020   Phase 2   NCT04302103   China;
RECOMBINANT NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN PRODUCED IN E.COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE   
   REGENERON PHARMACEUTICALS, INC.
      2021   Phase 3   EUCTR2020-003272-41-IT   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN   
   REGENERON PHARMACEUTICALS, INC.
      2021   Phase 3   EUCTR2020-003272-41-IT   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN   
   REGENERON PHARMACEUTICALS, INC.
      2021   Phase 3   EUCTR2020-003272-41-IT   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
REGN3918   
   REGENERON PHARMACEUTICALS, INC.
      2021   Phase 3   EUCTR2020-003272-41-IT   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
   Regeneron Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2020-003272-41-ES   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2022   Phase 3   EUCTR2020-003272-41-DE   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003272-41-PL   Australia;Belgium;Canada;Czechia;Denmark;France;Germany;Italy;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States;
RO5333787   
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-004436-21-IT   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States;
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-004436-21-NL   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States;
      2021   Phase 3   EUCTR2020-004436-21-DK   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States;
      2021   Phase 3   EUCTR2020-004436-21-DE   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States;
      -   Phase 3   EUCTR2020-004436-21-PL   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States;
      -   Phase 3   EUCTR2020-004436-21-FR   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States;
   Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-004436-21-ES   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States;
RTX   
   Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
      2019   -   ChiCTR1900024644   China;
RVT-1401   
   Immunovant Sciences GmbH
      2019   Phase 2   NCT03863080   Canada;United States;
Raptiva 100 mg/ml powder and solvent for solution for injection   
   Merck Serono International S.A.
      2009   -   EUCTR2007-001377-28-PT   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-NL   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-FR   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-DE   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-AT   Austria;France;Germany;Netherlands;Portugal;
Ravulizumab   
   ALEXION PHARMACEUTICALS INCORPORATED
      2019   Phase 3   EUCTR2018-003243-39-IT   Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States;
   Alexion Pharmaceuticals
      2019   Phase 3   NCT03920293   Austria;Canada;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Spain;Switzerland;United States;
   Alexion Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2018-003243-39-PT   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-003243-39-GB   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-003243-39-CZ   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003243-39-NL   Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003243-39-ES   Austria;Canada;Denmark;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Spain;Switzerland;United States;
      2019   Phase 3   EUCTR2018-003243-39-DK   Austria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003243-39-AT   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States;
Rituximab   
   Assistance Publique - Hôpitaux de Paris
      2008   Phase 2   NCT00774462   France;
   Department of NeurologyUniversity of Tokyo, Graduate School of Medicine
      2013   -   JPRN-UMIN000012089   Japan;
   FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
      2021   Phase 3   EUCTR2020-005619-35-IT   Italy;
   Fredrik Piehl
      2016   Phase 3   NCT02950155   Sweden;
   Tokushima University Hospital
      2015   -   JPRN-UMIN000016564   Japan;
   Yale University
      2014   Phase 2   NCT02110706   United States;
Rituximab (Rituxan)   
   University of Vermont
      2004   Phase 1/Phase 2   NCT00619671   United States;
Ro 533-3787/F01-06   
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-004436-21-NL   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States;
      2021   Phase 3   EUCTR2020-004436-21-DK   Argentina;Australia;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United States;
Rozanolixizumab   
   SUGIHARA Kazuhiro
      2021   Phase 3   JPRN-jRCT2021200038   Belgium;Canada;Czech Republic,;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;Taiwan;UK;US;
   UCB Biopharma SPRL
      2020   Phase 3   EUCTR2019-000969-21-ES   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000969-21-HU   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000968-18-HU   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000968-18-GB   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hong Kong;Hungary;Italy;Poland;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000968-18-ES   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002698-36-DK   Belgium;Canada;Czech Republic;Denmark;Germany;Spain;United States;
      2017   Phase 2   EUCTR2016-002698-36-DE   Belgium;Canada;Czech Republic;Denmark;Germany;Spain;United States;
      2017   Phase 2   EUCTR2016-002698-36-CZ   Belgium;Canada;Czech Republic;Denmark;Germany;Spain;United States;
      2017   Phase 2   EUCTR2016-002698-36-BE   Belgium;Canada;Czech Republic;Denmark;Germany;Spain;United States;
   UCB Biopharma SRL
      2021   Phase 3   NCT04650854   Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;Taiwan;United States;
      2020   Phase 3   EUCTR2019-000969-21-PL   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000969-21-IT   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000969-21-CZ   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States;
      2019   Phase 3   NCT04124965   Canada;Czechia;Denmark;France;Germany;Italy;Japan;Poland;Russian Federation;Spain;Taiwan;United States;
      2019   Phase 3   NCT03971422   Belgium;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000968-18-IT   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Poland;Russian Federation;Spain;Taiwan;United Kingdom;United States;
   UCB Japan Co., Ltd.
      2020   Phase 3   JPRN-JapicCTI-205350   Japan, Asia except Japan, North America, Europe;
      2020   Phase 3   JPRN-JapicCTI-205207   Japan, Asia except Japan, North America, Europe;
SALBUTAMOL SULFATE PH. EUR.   
   Aarhus University Hospital
      2019   Phase 3   EUCTR2019-000895-40-DK   Denmark;
SAR442168   
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 3   EUCTR2021-003898-59-IT   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
   Sanofi-Aventis Recherche & Développement
      2022   Phase 3   EUCTR2021-003898-59-PL   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-003898-59-ES   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-003898-59-HU   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
Salbutamol 4Mg Tablet   
   University of Aarhus
      2019   Phase 2/Phase 3   NCT03914638   Denmark;
Salbutamol WZF   
   Aarhus University Hospital
      2019   Phase 3   EUCTR2019-000895-40-DK   Denmark;
Satralizumab   
   Hoffmann-La Roche
      2021   Phase 3   NCT04963270   Argentina;Australia;Brazil;Canada;China;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Turkey;United States;
   Ivana Vodopivec
      2021   Phase 3   JPRN-jRCT2021210024   Argentina;Australia;Brazil;Canada;China;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Republic of Korea;Russian Federation;Spain;Taiwan;Turkey;United States;
Sodium Chloride solution   
   Fredrik Piehl
      2016   Phase 3   NCT02950155   Sweden;
Soliris   
   Alexion Pharmaceuticals, Inc.
      2021   Phase 3   EUCTR2016-001384-37-NL   Canada;Germany;Japan;Netherlands;United States;
      2020   Phase 3   EUCTR2016-001384-37-DE   Canada;Germany;Japan;Netherlands;United States;
Subcutaneous immunoglobulin (SCIG)   
   University Health Network, Toronto
      2020   Phase 2   NCT04728425   Canada;
Subcutaneous immunoglobulins   
   St. Louis University
      2011   Phase 1   NCT01828294   United States;
Symptomatic Treatment, Steroids, Immunosuppressive Agents( azathioprine, tacrolimus, Mycophenolate Mofetil)   
   Tang-Du Hospital
      2019   -   NCT04182984   China;
Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)   
   Da, Yuwei, M.D.
      2017   -   NCT04101578   China;
Syngeneic Bone Marrow Transplantation   
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
T-peptide-CRM197 conjugate   
   CuraVac Europe SA
      2017   Phase 2;Phase 3   EUCTR2017-000323-27-NL   Belgium;Netherlands;
      2017   Phase 2;Phase 3   EUCTR2017-000323-27-BE   Belgium;Netherlands;
TAK-079   
   Takeda
      2020   Phase 2   NCT04159805   Canada;Italy;Poland;Serbia;Spain;United States;
TAK-079, TSF-021, TSF79   
   MILLENNIUM PHARMACEUTICALS, INC.
      2020   Phase 2   EUCTR2019-003383-47-IT   Canada;Italy;Poland;Serbia;Spain;United States;
Tacrolimus   
   Astellas Pharma Inc
      2006   Phase 3   NCT00309101   Japan;
      2006   Phase 3   NCT00309088   Japan;
   Department of Neurology, Chiba University Graduate School of Medicine
      2012   -   JPRN-UMIN000007679   Japan;
      2012   -   JPRN-UMIN000007671   Japan;
   Kansai medical university
      2014   -   JPRN-UMIN000015019   Japan;
Tacrolimus capsule   
   Astellas Pharma Inc
      2011   Phase 3   NCT01325571   China;
Tetanus vaccin   
   Leiden University Medical Center
      2015   Phase 4   EUCTR2014-004344-35-NL   Netherlands;
Thymectomy plus prednisone   
   University of Alabama at Birmingham
      2006   Phase 3   NCT00294658   Argentina;Australia;Brazil;Canada;Chile;Germany;Ireland;Italy;Japan;Mexico;Netherlands;Poland;Portugal;South Africa;Spain;Taiwan;Thailand;United Kingdom;United States;
Tocilizumab   
   Department of Neurology, The Second Affiliated Hospital of Air Force Medical University
      2021   -   ChiCTR2100043273   China;
Tocilizumab Injectable Product   
   Tang-Du Hospital
      2021   Phase 2   NCT05067348   China;
Tofacitinib   
   Huashan Hospital
      2020   Early Phase 1   NCT04431895   China;
Tolebrutinib   
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 3   EUCTR2021-003898-59-IT   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
   Sanofi-Aventis Recherche & Développement
      2022   Phase 3   EUCTR2021-003898-59-PL   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-003898-59-ES   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-003898-59-HU   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
Tolebrutininb   
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 3   EUCTR2021-003898-59-IT   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
   Sanofi
      2021   Phase 3   NCT05132569   Hungary;United Kingdom;United States;
   Sanofi-Aventis Recherche & Développement
      2022   Phase 3   EUCTR2021-003898-59-ES   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-003898-59-HU   Canada;China;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States;
UCB7665   
   UCB Biopharma S.P.R.L.
      2017   Phase 2   NCT03052751   Belgium;Canada;Czechia;Denmark;Germany;Spain;United States;
   UCB Biopharma SPRL
      2020   Phase 3   EUCTR2019-000969-21-ES   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000969-21-HU   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000968-18-HU   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000968-18-GB   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hong Kong;Hungary;Italy;Poland;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000968-18-ES   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002698-36-ES   Belgium;Canada;Czech Republic;Denmark;Germany;Spain;United States;
      2017   Phase 2   EUCTR2016-002698-36-DK   Belgium;Canada;Czech Republic;Denmark;Germany;Spain;United States;
      2017   Phase 2   EUCTR2016-002698-36-DE   Belgium;Canada;Czech Republic;Denmark;Germany;Spain;United States;
      2017   Phase 2   EUCTR2016-002698-36-CZ   Belgium;Canada;Czech Republic;Denmark;Germany;Spain;United States;
      2017   Phase 2   EUCTR2016-002698-36-BE   Belgium;Canada;Czech Republic;Denmark;Germany;Spain;United States;
   UCB Biopharma SRL
      2021   Phase 3   EUCTR2020-003230-20-BE   Belgium;Canada;China;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-003230-20-PL   Belgium;Canada;China;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-003230-20-IT   Belgium;Canada;China;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-003230-20-HU   Belgium;Canada;China;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-003230-20-GB   Belgium;Canada;China;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-003230-20-DK   Belgium;Canada;China;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-003230-20-DE   Belgium;Canada;China;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000969-21-PL   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000969-21-IT   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000969-21-GB   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000969-21-DE   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000969-21-CZ   Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000969-21-DK   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000968-18-PL   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Poland;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000968-18-IT   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Poland;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000968-18-DK   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Poland;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000968-18-DE   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Poland;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000968-18-CZ   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Poland;Russian Federation;Spain;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000968-18-BE   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Poland;Russian Federation;Spain;Taiwan;United Kingdom;United States;
Ultomiris   
   ALEXION PHARMACEUTICALS INCORPORATED
      2019   Phase 3   EUCTR2018-003243-39-IT   Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States;
   Alexion Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2018-003243-39-PT   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-003243-39-GB   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-003243-39-CZ   Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003243-39-NL   Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003243-39-DK   Austria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States;
Ultomiris 1,100 mg/11 mL   
   Alexion Pharmaceuticals Incorporated
      2019   Phase 3   EUCTR2018-003243-39-DE   Austria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States;
Uplizna   
   Viela Bio, Inc.
      2021   Phase 3   EUCTR2020-000949-14-DK   Argentina;Belarus;Brazil;Canada;China;Denmark;France;Germany;India;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United States;
      2021   Phase 3   EUCTR2020-000949-14-DE   Argentina;Belarus;Brazil;Canada;China;Denmark;France;Germany;India;Israel;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United States;
Velamox   
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2   EUCTR2021-001229-26-IT   Canada;Germany;Italy;Korea, Republic of;Spain;Taiwan;United States;
Velcade®   
   Charité - Universitätsmedizin Berlin
      2014   Phase 2   EUCTR2013-005362-19-DE   Germany;
Zilucoplan   
   Ra Pharmaceuticals, Inc.
      2020   Phase 3   EUCTR2019-001565-33-IT   Canada;France;Germany;Italy;Japan;Norway;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001565-33-ES   Canada;France;Germany;Italy;Japan;Norway;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001564-30-IT   Canada;France;Germany;Italy;Japan;Norway;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001564-30-ES   Canada;France;Germany;Italy;Japan;Norway;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001564-30-DE   Canada;France;Germany;Italy;Japan;Korea, Republic of;Norway;Poland;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001565-33-GB   Canada;France;Germany;Italy;Japan;Norway;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001564-30-GB   Canada;France;Germany;Italy;Japan;Norway;Spain;United Kingdom;United States;
   Ra Pharmaceuticals, Inc. (now part of UCB)
      2021   Phase 3   EUCTR2019-001565-33-PL   Canada;France;Germany;Italy;Japan;Korea, Republic of;Norway;Poland;Spain;United Kingdom;United States;
Zilucoplan (RA101495)   
   Ra Pharmaceuticals
      2019   Phase 3   NCT04225871   Canada;France;Germany;Italy;Japan;Norway;Poland;Spain;United Kingdom;United States;
      2019   Phase 3   NCT04115293   Canada;France;Germany;Italy;Japan;Norway;Poland;Spain;United Kingdom;United States;
      2017   Phase 2   NCT03315130   Canada;United States;